TR Co., Ltd., a digital-based medical device company, announced on the 2nd that it was finally selec.. – MK

TR Co., Ltd., a digital-based medical device company, announced on the 2nd that it was finally selected in the new healthcare business field in the “2026 Ultra Gap Startup Program” organized by the Ministry of SMEs and Startups.

DIPS is a project that fosters start-up companies in 12 new industries in six strategic industries to lead the global market. Through this selection, TR will receive various benefits such as technology advancement and investment attraction linkage, including up to 600 million won in subsidies for three years.

The ‘multi-modal deep learning-based respiratory disease decision-making support system’, which is the core of this task, aims to provide AI with a specialist-level reading guide beyond the simple dissemination of existing respiratory disease examiners. In particular, by combining CNN-based waveform analysis and RAG-based AI agent technology, we plan to dramatically improve the quality of diagnosis so that even general clinic-level medical institutions can immediately check detailed diagnosis and prescription guides at the level of advanced general hospitals. Through this, it aims to provide a high level of respiratory disease management services to medical vulnerable areas and classes.

Currently, TR’s digital-based simple precision lung function test “The Spirokit” reduces reluctance to test because it makes it relatively easier to test lung function tests avoided by medical staff and patients due to the difficult test method. Primary medical institutions are also convenient to use, increasing patients’ access to lung function tests. In addition, through this DIPS, we plan to strengthen AI functions so that respiratory diseases can be diagnosed, read, and prescribed more conveniently and accurately.

“This is the result of being recognized for its technology through the selection of DIPS,” said Kim Byung-soo, CEO of TR. “We want to take this opportunity to expand the base of lung function tests by developing and upgrading the system, and to promote the excellence of domestic medical devices in the global market.”